Scientists from the Ludwig Boltzmann Institut for Cancer Research have contributed to identify higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published in EMBO Molecular Medicine, show that elevated levels of the protein Ret, which is short for “Rearranged during transfection”, are associated with a lower likelihood of survival for breast cancer patients in the years following surgery to remove tumours and cancerous tissue.
A new stand alone project was accepted for funding at the board meeting of the Austrian Science Fund on June 25, 2013.
At the 4th Annual Meeting of the European Research Initiative on ALK-related Malignancies (ERIA) on June 27-28, 2013 Moriggl and Kenner joined an international group of leading scientists in leukemia research.
Professor Lukas Kenner of the Ludwig Boltzmann Institute for Cancer Research (LBI-CR) in Vienna receives the 2013 Research Award of the "Central European Society for Anticancer Drug Research" (CESAR).
Cancer researchers take the hidden activities of tumor cells into their sights
Researchers at the LBI-CR strive actively to supplement the financial support of the LBG and the Partners with funds from external sources. This provides leverage on the funds provided and by continuous peer review ensures internationally competitive research is performed within our institute. The director of the LBI-CR Richard Moriggl stresses: “External evaluation by international acknowledged researchers in the field of cancer research have consistently commended the LBI-CR on its outstanding scientific performance.